Myriad Genetics 10-Kyear ended 2025-12-31

Executive Summary

Myriad Genetics is investing in cancer diagnostics and broader prenatal testing, but FY2025 showed that higher test volume does not guarantee revenue growth when reimbursement per test falls. Revenue declined 1.6% to $824M, driven chiefly by a GeneSight coverage change, while $319M of impairments widened the GAAP net loss to $366M. Operating cash flow turned slightly positive, but investment spending exceeded it and the higher cash balance largely reflects secured borrowing. The investor case rests on new-test adoption and improved collections; its main threats are persistent reimbursement pressure, launch delays and the cost of financing growth.

Key Financial Highlights

• Revenue mix: Hereditary Cancer grew to $372M and Prenatal to $186M; Mental Health fell 15% to $144M despite higher volume, principally because UnitedHealthcare changed GeneSight coverage. Tumor Profiling declined to $122M, partly reflecting the earlier EndoPredict divestiture.
• Underlying operations: Excluding each year’s impairment charges, operating losses were ≈$67.8M in FY2025 and $66.7M in FY2024—broadly flat rather than improved. FY2024 also included $21.5M of revenue adjustments for tests completed in prior periods, making reported growth an imperfect measure of current testing activity.
• Investment and cash conversion: In addition to $15.6M of capital expenditures, Myriad capitalized $11.8M of intangible assets; operating cash flow less both outlays was $(25.6)M. R&D was $107M, down from $113M, ahead of management’s planned increase in 2026.
• Financing and dilution: The new facility had $125M principal outstanding and a 10.4% year-end interest rate; interest expense rose to $10.5M from $2.8M. Stock-based compensation was $35.2M, while shares outstanding increased to 93.5M from 91.3M.

Business Developments

Management is directing resources toward the Cancer Care Continuum, Prenatal Health and Mental Health, with an emphasis on clinical evidence, commercial reach and operating efficiency. Myriad completed its transition to next-generation laboratories in 2025; management expects automation and scale benefits, but those benefits have yet to produce operating profitability.

The proposed growth portfolio spans Precise MRD for cancer monitoring, an AI-enabled prostate diagnostic licensed from PATHOMIQ and a liquid-biopsy companion-diagnostic collaboration with SOPHiA GENETICS. In Prenatal Health, FirstGene entered limited early access, with a full launch expected in 2026. These initiatives could diversify growth away from established tests, but require validation, coverage and clinician adoption before they materially contribute. Myriad expects to discontinue U.S. EndoPredict sales in H1 2026, further shifting the oncology portfolio toward newer offerings.

The federal laboratory-developed-test rule was vacated in 2025, removing its immediate phase-in deadlines. Separately, legislation deferred potential Medicare payment reductions through 1/30/2027; neither development settles longer-term regulatory or pricing uncertainty.

Risk Assessment

• Reimbursement and collections: Private third-party payors provide ≈61% of revenue, and UnitedHealthcare’s GeneSight policy has already reduced revenue per test; further coverage denials, rate cuts or recoupments could impair both sales and cash receipts.
• Liquidity and covenants: The secured facility has up to $75M of delayed-draw capacity, but its 10.4% year-end rate and minimum trailing-12-month revenue covenant—rising from $615M at 12/31/2025 to $974M by 12/31/2029—could constrain flexibility if growth stalls.
• Product execution: New assays depend on clinical evidence, reimbursement and adoption; FirstGene or Precise MRD delays would postpone returns on planned R&D and commercial spending.
• Valuation: The $319M impairment reflects weaker forecasts and market capitalization; remaining goodwill of $51.6M and net intangible assets of $153M remain exposed to further forecast deterioration.
• Laboratory and technology continuity: Each test is performed at a single laboratory without a redundant facility for that test, so a site outage, supplier disruption or systems failure could interrupt processing and billing.
• Compliance and leadership: Genetic-data, laboratory and healthcare-payment rules create penalty and recoupment exposure, while changes in the chief executive, finance, commercial and operating roles during 2025 add execution risk.

Strategic Outlook and Investor Actionables

Myriad’s near-term task is to turn portfolio investment and modest volume growth into collected revenue without increasing cash burn. New oncology and prenatal products offer upside, but reimbursement—not testing demand alone—will determine whether growth improves profitability.

• GeneSight and collections: Monitor Mental Health revenue per test and operating cash flow; recovery would show whether commercial execution can offset the coverage change.
• Launch conversion: Monitor FirstGene’s full commercial launch and progress toward Precise MRD adoption; delays would weaken the case for higher R&D spending.
• Cash and covenant headroom: Monitor FCF, borrowing and trailing-12-month revenue against the rising covenant; improvement without additional debt or dilution would strengthen the investment case.